Gilmore O'Neill, M.B., M.M.Sc
2020
Compensation breakdown
| Non-Equity Incentive Plan | $293,164 |
|---|---|
| Option Awards | $2,131,159 |
| Salary | $583,277 |
| Stock Awards | $766,949 |
| Other | $15,500 |
| Total | $3,790,049 |
MMSc received $2.1M in option awards, accounting for 56% of the total pay in 2020.
MMSc also received $293.2K in non-equity incentive plan, $583.3K in salary, $766.9K in stock awards and $15.5K in other compensation.
Rankings
In 2020, Gilmore O'Neill, M.B., M.M.Sc's compensation ranked 3,032nd out of 13,090 executives tracked by ExecPay. In other words, MMSc earned more than 76.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,032 out of 13,090 | 77th |
Division Manufacturing | 1,183 out of 5,617 | 79th |
Major group Chemicals And Allied Products | 448 out of 2,248 | 80th |
Industry group Drugs | 388 out of 1,948 | 80th |
Industry Pharmaceutical Preparations | 289 out of 1,453 | 80th |
Pay ratio
| Gilmore O'Neill, M.B., M.M.Sc's Pay | $3,790,049 |
|---|---|
| Median Employee's Pay | $275,247 |
| Pay Ratio | 14to 1 |
In 2020, the annual total compensation of Gilmore O'Neill, M.B., M.M.Sc was $3,790,049.
The annual total compensation of the median employee at Sarepta Therapeutics was $275,247.
The ratio of Gilmore O'Neill, M.B., M.M.Sc's pay to the pay of median employee was therefore 14 to one.
MMSc's colleagues
We found seven more compensation records of executives who worked with Gilmore O'Neill, M.B., M.M.Sc at Sarepta Therapeutics in 2020.
2020
Louise Rodino-Klapac
Sarepta Therapeutics
Chief Scientific Officer
2020
David Howton
Sarepta Therapeutics
General Counsel
2020
Ian Estepan
Sarepta Therapeutics
Chief Financial Officer
2020
Sandesh Mahatme
Sarepta Therapeutics
Chief Financial Officer
2020
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
2020
Joseph Bratica
Sarepta Therapeutics
Vice President, Corporate Controller
2020
William Ciambrone
Sarepta Therapeutics